Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy-Reference-Cited by-同舟云学术

Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy

Published:2007-10-23 Issue:1 Volume:7 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Fr Brunsvig Paal,Andersen Anders,Aamdal Steinar,Kristensen Vessela,Olsen Harald

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/article/10.1186/1471-2407-7-197/fulltext.html

Reference29 articles.

1. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK: Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline. Lung Cancer. 2005, 50: 355-374. 10.1016/j.lungcan.2005.06.010.

2. Hainsworth JD, Burris HA, Litchy S, Morrissey LH, Barton JH, Bradof JE, Greco FA: Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer. 2000, 89: 328-333. 10.1002/1097-0142(20000715)89:2<328::AID-CNCR17>3.0.CO;2-F.

3. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M: Phase III Study of Second-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel. J Clin Oncol. 2005, 23: 8389-8395. 10.1200/JCO.2005.02.3739.

4. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P: Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem. 1991, 34: 992-998. 10.1021/jm00107a017.

5. Ringel I, Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991, 83: 288-291. 10.1093/jnci/83.4.288.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics;Pharmaceutics;2023-12-04

2. Utilizing two-dimensional monolayer and three-dimensional spheroids to enhance radiotherapeutic potential by combining gold nanoparticles and docetaxel;Cancer Nanotechnology;2023-10-19

3. Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistance;Cancer Drug Resistance;2023

4. Lipid-Nanoparticle-Mediated Delivery of Docetaxel Prodrug for Exploiting Full Potential of Gold Nanoparticles in the Treatment of Pancreatic Cancer;Cancers;2022-12-13

5. Lipid Nanoparticle Mediated Delivery of Docetaxel Prodrug for Exploiting Full Potential of Gold Radiosensitizers in the Treatment of Pancreatic Cancer.;2022-10-14